Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 33

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 2025, the Company expensed $32,985 and $34,785, and paid $16,675 and $18,475 to the service organization for services performed, which is recognized in research and development expenses on the statement of operations.  As of June 30, 2025, the Company recognized $16,310 in accounts payable and $1,800 in accrued expenses.

Note 12. Segments

The Company has a single segment and allocates resources based on cash resources and operating expense projections. The table below summarizes the significant expense categories regularly reviewed by the Company’s president and chief executive officer, who is the Company’s chief operating decision maker (“CODM”), for the three and six months ended June 30, 2025 and 2024:

12

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Research and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $7 $— $61 INVINCIBLE-2 Study (Phase 2 Breast)— 117 — 221 INVINCIBLE-3 Study (Phase 3 Sarcoma)788 1,970 2,383 3,388 INVINCIBLE-4 Study (Phase 2 Breast)134 315 197 315 Other clinical trial expenses14 58 14 58 Clinical trial expenses936 2,467 2,594 4,043 Contract manufacturing6 417 29 631 Salaries and benefits related292 448 622 842 Consulting & Other(a)44 14 62 79 Stock-based compensation263 217 423 783 Research and development expenses1,541 3,563 3,730 6,378 General and administrative expenses:Salaries and benefits related234 300 464 624 Legal fees74 175 242 433 Audit fees88 58 165 173 Consulting121 167 317 339 Insurance160 275 316 561 Other(b)106 157 209 341 Stock-based compensation381 374 656 963 General and administrative expenses1,164 1,506 2,369 3,434 Loss from operations(2,705)(5,069)(6,099)(9,812)Other segment items(c)168 98 215 238